Severe covid-19 pneumonia: pathogenesis and clinical management

AH Attaway, RG Scheraga, A Bhimraj, M Biehl… - bmj, 2021 - bmj.com
Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - pnas.org
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

[PDF][PDF] Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19): временные методические рекомендации

ЕГ Камкин - ЕГ Камкин.–2020.–226 с, 2020 - vakcina.ru
В конце 2019 г. в Китайской Народной Республике (КНР) произошла вспышка новой
коронавирусной инфекции с эпицентром в городе Ухань (провинция Хубэй). Всемирная …

[PDF][PDF] Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (covid-19)

ЕГ Камкин, НА Костенко, ЕВ Каракулина, СН Авдеев… - Kamkin EG et al, 2020 - opc33.ru
В конце 2019 г. в Китайской Народной Республике (КНР) произошла вспышка новой
коронавирусной инфекции с эпицентром в городе Ухань (провинция Хубэй). Всемирная …

[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)

A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

LJ Stevens, AJ Pruijssers, HW Lee… - Science translational …, 2022 - science.org
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

RL Gottlieb, A Nirula, P Chen, J Boscia, B Heller… - Jama, 2021 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

JM Dan, J Mateus, Y Kato, KM Hastie, ED Yu, CE Faliti… - Science, 2021 - science.org
INTRODUCTION Immunological memory is the basis for durable protective immunity after
infections or vaccinations. Duration of immunological memory after severe acute respiratory …

[HTML][HTML] Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial

E López-Medina, P López, IC Hurtado, DM Dávalos… - Jama, 2021 - jamanetwork.com
Importance Ivermectin is widely prescribed as a potential treatment for COVID-19 despite
uncertainty about its clinical benefit. Objective To determine whether ivermectin is an …